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Background: Peroxisome proliferator-activated receptor gamma coactivator-1α (PPARGC1A/ PGC-1α) is a
ligand-activated transcription factor belonging to the nuclear hormone receptor superfamily. The activity of PGC-1α
or genetic variations in the gene encoding the enzyme may contribute to individual variations in mitochondrial
function and insulin resistance or diabetes. The objective of this study was to assess the extent to which PPARGC1A
(rs8192678) and serum uric acid (UA) and its interaction impact on T2DM susceptibility in Chinese Han population.
Method: We conducted a study in a cohort that included 1166 T2DM patients and 1135 controls, and was
genotyped for the presence of the PPARGC1A rs8192678 polymorphisms. Genotyping was performed by iPLEX
technology. The association between rs8192678 or UA and T2DM was assessed by univariate and multivariate
logistic regression (MLR) analysis controlling for confounders. The interaction between rs8192678 and UA for T2DM
susceptibility was also assessed by MLR analysis.
Results: The generalized linear regression analysis failed to show an association between the PPARGC1A rs8192678
polymorphisms and T2DM. Interestingly, the present study provided data suggesting that the minor A-allele of
PPARGC1A (rs8192678) had a protective effect against T2DM in subjects with higher level of UA (ORint =1.50 95%
CI: 1.06-2.12 for allele and P = 0.02, ORint =1.63 95% CI: 1.17-2.26 for genotype and P = 0.004).
Conclusion: The combination of higher level of UA and PPARGC1A (rs8192678) was an independent predictor for
T2DM.
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Type 2 diabetes mellitus (T2DM) is a complex metabolic
disorder characterized by hyperglycemia as a result of
pancreatic beta cell dysfunction and insulin resistance [1].
There is evidence demonstrating that genetic determi-
nants as well as environmental factors may play a role in
the pathophysiology of T2DM. Identifying rare and com-
mon genetic variants contributing to risk of or protection
from T2DM will help uncover the complex mechanisms* Correspondence: wenjie065@126.com
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unless otherwise stated.underlying T2DM, and provide crucial implications for
the development of personalized medicine for diabetes
mellitus [2].
Peroxisome proliferator-activated receptor gamma
coactivator-1α (PPARGC1A/PGC-1α) is a ligand-activated
transcription factor belonging to the nuclear hormone
receptor superfamily, named after its ability to bind che-
micals known to induce peroxisome proliferation [3].
Numerous studies have identified an important role for
PPARGC1A in gluconeogenesis and insulin sensitivity
as well as the beta-oxidation of fatty acids in the liver [4].
Plasma fasting insulin has been linked to the chromo-
somal region where the PPARGC1A gene is located [5],
which verify the hypothesis that the gene may be a func-
tional and positional candidate for T2DM. Moreover,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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thelial migration, thus potently inhibit endothelial func-
tion and angiogenesis, which further contribute to
multiple aspects of vascular dysfunction in diabetes [6].
Associations of PPARGC1A variants with a range of other
metabolic traits, including glucose concentrations, dyslip-
idemia and obesity have been reported [7-10]. The
PPARGC1A rs8192678 polymorphism encodes a missense
amino acid change, however, the activity of PGC-1α or
genetic variations in the gene may contribute to individual
variations in mitochondrial function and insulin resistance
or diabetes [11,12]. Recently, a new window has opened
on the possible associations of PPARGC1A (rs8192678)
with several metabolic related traits [13]. Furthermore,
PPARGC1A (rs8192678) has also been found to be associ-
ated with a higher risk of T2DM in Indian and East Asian
populations [14,15]. Uncovering the effect of PPARGC1A
variant on the susceptibility of T2DM in Chinese popula-
tion and how it functions within the regulatory network
will deepen our understanding of the biological roles of
PPARGC1A.
In the relevant network, cellular PPARGC1A is regu-
lated by signaling inputs that increase the transcription of
the PPARGC1A gene and activity of PPARGC1A protein
[16]. Emerging evidence has been provided to illustrate
that PPARGC1A transcription increases with exercise,
cold exposure, fasting and electro acupuncture [17-19]. It
is thereby feasible that environment stimuli which could
irritate the transcription of PPARGC1A gene also partici-
pate in modulation of T2DM susceptibility.
Serum uric acid (UA), as the final oxidation product of
purine catabolism, has been associated with various
clinical conditions, such as diabetes mellitus (DM), ath-
erosclerotic disease and abdominal obesity [20-23]. Signifi-
cant interactions between UA and age, triglycerides, as
well as metabolic syndrome have also been reported in
numerous studies [24-26]. There are few studies available
on the effect of the interaction between UA and genetic
variants on diseases. The objective of this study was to
clarify whether the rs8192678 polymorphism or UA is as-
sociated with T2DM in Chinese population and to deter-




The study protocol was approved by the Ethics Commit-
tee of Huashan Hospital, Shanghai, China. We carried out
a study in a random sample of Chinese individuals to
evaluate the association between PPARGC1A (rs8192678)
and T2DM, as well as to determine whether the variant
interacts with UA to influence T2DM susceptibility. Par-
ticipants enrolled in the cohort, including 1166 T2DM pa-
tients and 1135 controls, were of Southern Han Chineseancestry residing in the Shanghai metropolitan area.
T2DM patients registered in the analysis were recruited
from the Endocrinology and Metabolism outpatient clinics
at Fudan University Huashan Hospital in Shanghai.
Written consent was obtained from all patients before the
study.
Measurement
The subjects were interviewed for the documentation of
medical histories, medications and regular physical exami-
nations. Systolic and diastolic blood pressure (BP) values
were the means of two physician-obtained measurements
on the left arm of the seated participant. Body mass index
(BMI) was calculated as the weight in kilograms divided
by the square of height in meters. All participants under-
went a complete hematological examination in the fasting
state. Plasma glucose was quantified by the glucose
oxidase-peroxidase procedure. Serum total cholesterol
(TC), triglyceride (TG), high-density lipoprotein (HDL)
cholesterol, urea nitrogen (UN), uric acid (UA) and
alanine transaminase (ALT) levels were measured by an
enzymatic method with a chemical analyzer (Hitachi
7600-020, Tokyo, Japan). Low-density lipoprotein (LDL)
cholesterol levels were calculated using the Friedewald
formula. The day-to-day and inter-assay coefficients of
variation at the central laboratory in our hospital for all
analyses were between 1% and 3%.
Definition
Hypertension (HT) was defined as blood pressure ≥ 140/
90 mmHg or history of hypertension medication. The
classification of serum uric acid (UA) was based on the
Chinese criteria [24]: UA ≥ 420 umol/L. Diabetes was de-
fined according to 1999 WHO criteria [27]: fasting plasma
glucose ≥ 7.0 mmol/L, and/or 2-hour plasma glucose
≥ 11.1 mmol/L in oral glucose tolerance test (OGTT).
Known subtypes of diabetes were excluded based on anti-
body measurements and inheritance. The non-diabetic
unrelated individuals meeting the following criterions
were identified as the control population: 1) no family his-
tory of diabetes; 2) ≥ 45 years of age; 3) normal glucose
tolerance verified by OGTT. The clinical characteristics of
participants are summarized in Table 1.
SNP genotyping
Peripheral venous blood samples were collected from all
study subjects, and the genomic DNA was isolated from
whole blood by proteinase K digestion followed by
phenol–chloroform extraction. PPARGC1A (rs8192678)
was genotyped using iPLEX (Sequenom, San Diego, CA,
USA) and detected by matrix-assisted laser desorption/
ionization-time of flight mass spectrometry in a total of
2301 Chinese Han individuals. The genotype frequency
was in Hardy-Weinberg equilibrium (P > 0.05) and there
Table 1 The clinical characteristics of subjects
Variable Diabetes Control
N 1166 1135
Age 65.46 ± 10.56 59.09 ± 7.85
Sex (male/female) 456/710 352/783
Height 160.2 ± 8.64 161.09 ± 7.65
Weight 64.85 ± 10.71 62.78 ± 10.15
SBP 139.52 ± 19.92 126.44 ± 16.92
DBP 82.88 ± 10.98 80.52 ± 10.13
UN 6.08 ± 1.63 5.62 ± 1.37
UA 0.30 ± 0.08 0.31 ± 0.08
FPG 8.39 ± 3.03 5.22 ± 0.38
PPG 15.05 ± 5.34 6.03 ± 1.04
TC 5.43 ± 1.11 5.35 ± 1.00
TG 2.00 ± 1.46 1.47 ± 1.06
HDL 1.29 ± 0.34 1.43 ± 0.36
LDL 3.11 ± 0.86 3.10 ± 0.79
ALT 28.44 ± 16.08 24.04 ± 13.69
rs8192678 (A/G) 490/670 475/646
Note: SBP-systolic blood pressure, DBP-diastolic blood pressure, UN-urea
nitrogen, UA-uric acid, FPG-fasting plasma glucose, PBG-postprandial blood
glucose, TC-total cholesterol, TG-triglyceride, HDL-high density lipoprotein,
LDL-low density lipoprotein, ALT-alanine transaminase.
Table 2 Univariate logistic regression analysis for diabetes
Variable β S.E. P Value OR 95% CI
Age 0.07 0.003 <0.001 1.07 1.07-1.08
Sex −0.35 0.06 <0.001 0.70 0.62-0.80
BMI 0.59 0.08 <0.001 1.81 1.54-2.14
HT 1.21 0.09 <0.001 3.36 2.83-3.99
TC 0.07 0.03 0.01 1.07 1.02-1.14
TG 0.46 0.03 <0.001 1.59 1.48-1.70
UN 0.21 0.02 <0.001 1.24 1.19-1.29
UA 0.03 0.09 0.74 1.03 0.87-1.22
PPARGC1A −0.005 0.06 0.93 0.99 0.88-1.12
Note: PPARGC1A with SNP (rs8192678), BMI- body mass index, TC-total
cholesterol, TG-triglyceride, UN-urea nitrogen, UA-uric acid, HT-Hypertension.
Table 3 The interaction effect analysis of UA and allele of
PPARGC1A (rs8192678) for diabetes
Variable β S.E. P Value OR 95.0% C.I
UA −0.12 0.11 0.28 0.89 0.71-1.10
rs8192678(A/G) −0.06 0.06 0.32 0.94 0.83-1.06
UA by rs8192678(A/G) 0.41 0.18 0.02 1.50 1.06-2.12
Note: Variable - UA, PPARGC1A (rs8192678), UA by PPARGC1A (rs8192678);
Adjusted for Age, Sex, HT, BMI.
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samples were compared across plates.
Statistical analysis
The Kolmogorov-Smirnov test was used to determine
whether continuous variables followed a normal distribu-
tion. Variables that were not normally distributed were
log-transformed to approximate normal distribution for
analysis. Results are described as mean ± SD or median
unless stated otherwise. Differences in variables between
T2DM and control were determined by unpaired t-test.
Between groups differences in properties were accessed by
χ2 analysis. Univariate logistic regression was performed
to determine variables associated with T2DM and to esti-
mate confounding factors possibly disturbing the relation
of UA and/or PPARGC1A to T2DM. Multivariable logistic
regression (MLR) was carried out to control potential con-
founders for determining independent contribution of
variables to T2DM. For interaction analysis, MLR was
conducted to include two main variables and its inter-
action item to determine the interaction effect. In order to
better investigate the interaction between UA and
PPARGC1A on T2DM, we performed two analyses ac-
cording to alleles and genotypes of PPARGC1A that were
present in the study population by additive model. Odds
ratios (OR) with 95% confidence intervals (CI) were calcu-
lated as measures of association of UA and/or PPARGC1A
with T2DM. Results were analyzed using the StatisticalPackage for Social Sciences for Windows version 16.0
(SPSS, Chicago, IL, USA). Tests were two-sided and a
p-value of < 0.05 was considered significant.
Results
Clinical characteristics of subjects
The baseline clinical characteristics of the 2301 subjects
were listed in Table 1. There are 456 males and 710
females (mean age, 65.46 ± 10.56 years) in cases and 352
males and 783 females (mean age, 59.09 ± 7.85 years) in
controls. Diabetic patients had more weight than controls.
SBP, DBP, FPG, PPG, TC and TG levels were higher in
cases than those of controls, while HDL level was lower in
cases. Serum UA, ALT and LDL levels were similar be-
tween the two groups. The minor allele (A) frequency of
PPARGC1A was 42.24% and 42.37% in cases and controls,
respectively.
Univariate and multiple logistic regression analysis for
diabetes
To estimate the association of various clinical factors and
T2DM, univariate logistic regression models were devel-
oped to include age, sex, hypertension, lipid profiles, UA
and the rs8192678 polymorphisms (Table 2). The univari-
ate logistic analyses indicated that age, sex, BMI, hyperten-
sion and TC were significantly associated with T2DM
(P < 0.05 for all), however, there were no significant associ-
ation of UA and SNP (rs8192678) with T2DM (P = 0.744
and 0.928, respectively). The proportion of T2DM was
52.17% and 51.75% in low UA group and high UA group,
Figure 1 The interaction effect analysis of UA and PPARGC1A for diabetes.
Wu et al. Diabetology & Metabolic Syndrome 2014, 6:107 Page 4 of 6
http://www.dmsjournal.com/content/6/1/107respectively, but the difference was not statistically signifi-
cant between the two groups (P = 0.744).
UA by PPARGC1A interaction analysis for diabetes
The interaction item between UA and PPARGC1A, as well
as the interaction effect were detected in MLR models
after adjustment for relevant potential confounders, show-
ing a certain relationship between them (P = 0.02, ORInt =
1.50, 95% CI 1.06-2.12, shown in Table 3 and Figure 1). In
model of rs8192678 with allele variable, MLR models were
developed to include the two main effect variables: UA
and rs8192678. In another model of rs8192678 with geno-
type variable, the interaction term of UA and rs8192678
was detected by the same method (P = 0.004, Table 4), as
well as the interaction effect (ORInt = 1.625, 95% CI 1.172-
2.255). In these two models, MLR models signified that
UA or rs8192678 alone was not significantly associated
with T2DM. The interaction term of UA and SNP
rs8192678 which was detected in the two models (allele
and genotype models) only confirmed a significant associ-
ation between this SNP and T2DM in high UA group (P =
0.018 for allele analysis and P < 0.01 for genotype analysis,
data not shown).Table 4 The interaction effect analysis of UA and
genotype of PPARGC1A (rs8192678) for diabetes
Variable β S.E. P Value OR 95.0% C.I
UA −0.19 0.19 0.33 0.83 0.57-1.20
rs8192678(AA/AG/GG) −0.04 0.07 0.60 0.96 0.84-1.10
UA by rs8192678 0.49 0.17 0.004 1.63 1.17-2.26
Note: Variable - UA, PPARGC1A (rs8192678), UA by PPARGC1A (rs8192678); Ad-
justed for Age, Sex, HT, BMI.Discussion
Our current study evaluated the association between
PPARGC1A and T2DM in a case-control trial, subjects
enrolled in which were of Chinese Han population includ-
ing 1166 T2DM patients and 1135 controls. Genotyping
was performed for PPARGC1A (rs8192678) in the cohort.
This is the first report to our knowledge of an interaction
analysis on T2DM susceptibility based on variables of UA
and PPARGC1A.
Defect in mitochondrial oxidative phosphorylation have
been linked to insulin resistance [28], and there is also evi-
dence suggesting that polymorphisms in PPARGC1A are
associated with an increased relative risk of type 2 dia-
betes, defects in insulin secretion, and lipid oxidation [29].
PPARGC1A is a transcriptional regulator of genes re-
sponsible for mitochondrial biogenesis and fat oxidation.
Consistently, PPARGC1A (rs8192678) was reported to be
associated with T2DM in a European population, as well
as diabetic nephropathy (DN) in an Asian Indian popula-
tion [30,31]. These additional findings, which so far have
been observed in numerous studies, showed that
PPARGC1A may be a potential genetic marker for T2DM.
In our present study, the interaction of rs8192678 (G
allele) and high concentration of UA conferred a high risk
of T2DM (OR in Tables 3 and 4, Figure 1), while a com-
bination of the A-allele and high UA concentration
seemed to protect against T2DM. However, there is little
evidence to demonstrate PPARGC1A (rs8192678) to be an
independent risk factor of T2DM. Such results may be at-
tributed to the limited number of participants which had
insufficient statistical power to detect a slight effect of
the common polymorphism in PPARGC1A on T2DM
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to detect the association between this PPARGC1A genetic
variant and T2DM. In addition, another possibility of this
puzzling phenomenon is the diverse ethnic/regional
backgrounds, that is, findings might vary by population
because of the underlying unobserved genetic variation.
As mentioned above, the PPARGC1A gene, transcrip-
tion of which increases with environment stimuli, is a
master regulator of mitochondrial genes. Interestingly, re-
cently studies showed an improved intrinsic mitochondrial
function in PPARGC1A-overexpressing mice, but only
when fatty acids are used as a substrate [32]. Associations
between PPARGC1A genotypes and alcohol consumption
have been observed in a Mediterranean population [33].
The persuasive arguments confirm the hypothesis that in-
take of alcohol and fatty acid infusion/supplementation
may influence T2DM risk through their modulation in
PPARGC1A transcription. On this basis, we suspected that
UA may also modify the transcription of PPARGC1A
which further regulate the morbidity of diabetes mellitus.
Our study is the first analysis to detect the interaction
effect of UA and PPARGC1A (rs8192678) on T2DM sus-
ceptibility. It is noteworthy that the risk imparted by the
wild G-allele was statistically significantly higher than that
of A-allele in subjects with higher levels of UA (P < 0.05
for allele analysis and P < 0.01 for genotype analysis), des-
pite the lack of a direct link between UA level and T2DM.
The amusing results prompted the speculation of possible
interaction between PPARGC1A (rs8192678) and UA level
in determining overall T2DM risk. However, the under-
lying mechanism is yet to be determined.
Several limitations of the study warrant comment. First,
subjects participated in the study were recruited from
Shanghai, so they may not have been representative of
China as a whole. Second, since our study was performed
on Chinese individuals, these findings may not be relevant
to people of other ethnicities. Also, it is important to con-
firm the verdict with additional investigations using a lar-
ger sample to systematically evaluate the likely interaction
effect of PPARGC1A variants and UA on T2DM risk.
In conclusion, the possible association of PPARGC1A
(rs8192678) with T2DM has not been confirmed in the
present study. Interestingly, the data also suggested that the
minor A-allele of PPARGC1A (rs8192678) had a protective
effect against T2DM in subjects with higher levels of UA.
However, a functional study, such as gene-targeting in mice,
is needed to clarify the role of PPARGC1A as a whole.
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